266 related articles for article (PubMed ID: 32116138)
1. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori.
Raimondi A; Sepe P; Claps M; Maccauro M; Aliberti G; Pagani F; Apollonio G; Randon G; Peverelli G; Seregni E; Verzoni E; Procopio G
Tumori; 2020 Oct; 106(5):406-412. PubMed ID: 32116138
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
4. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
8. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
9. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
10. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
11. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ; Agarwal N; Sartor O; Sternberg CN; Tombal B; Saad F; Miller K; Constantinovici N; Guo H; Reeves J; Jiao X; Sandström P; Verholen F; Higano CS; Shore N
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):306-313. PubMed ID: 35190653
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Weng WC; Huang LH; Tseng NC; Ou YC
J Formos Med Assoc; 2022 Oct; 121(10):1929-1937. PubMed ID: 35123846
[TBL] [Abstract][Full Text] [Related]
13. Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer.
Álvarez Pérez RM; Delgado García A; García Martínez S; Sanz Viedma S; Palacios Gerona H; Pajares Vinardel M; Jiménez-Hoyuela García JM
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(5):298-304. PubMed ID: 31362912
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
15. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Sartor O; Appukkuttan S; Weiss J; Tsao CK
Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
[TBL] [Abstract][Full Text] [Related]
17. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
18. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
19. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
